PEN-FAST工具在药师主导药物重整中的实施评估
本研究为多中心回顾性患病率研究,在2家社区医院评估药师主导药物重整中应用PEN-FAST识别低风险青霉素过敏的可行性。95例患者中74%被分类为低风险,但仅10%移除过敏标签、3%接受直接口服青霉素激发试验,提示实施可行但去标签和激发试验率仍低。
要点
- 药师主导PEN-FAST评估可识别多数低风险青霉素过敏患者
- 低风险患者中去标签率和直接口服激发试验率仍较低
- 需进一步将PEN-FAST整合入临床流程以促进抗菌药物管理
核心结论
- 药师主导的PEN-FAST实施是识别低风险青霉素过敏的可行策略,但过敏去标签和口服激发试验率仍低。
主要发现
- 95例接受评估的患者中,74%(n=70)被分类为低风险青霉素过敏(PEN-FAST评分<3)。
- 低风险患者中,10%(n=7)移除了过敏标签,3%(n=2)接受了直接口服青霉素激发试验。
- 2例接受直接口服青霉素激发试验的患者均耐受青霉素,无不良反应。
关键数值与推荐
- 低风险青霉素过敏定义为PEN-FAST评分<3。
- 主要结局为低风险青霉素过敏患者的比例,次要结局包括过敏去标签率和直接口服青霉素激发试验频率。
临床怎么用
- 在药师主导的药物重整中应用PEN-FAST可识别低风险青霉素过敏患者,为后续去标签和口服激发试验提供依据。
- 需进一步将PEN-FAST整合入临床工作流程,以提高过敏去标签和口服激发试验的实施率,促进抗菌药物管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Approximately 10% of US patients report a penicillin allergy, yet fewer than 1% have a true immunoglobulin E-mediated reaction. Mislabeled allergies contribute to unnecessary use of broad-spectrum antibiotics, increasing healthcare costs, hospital stays, antimicrobial resistance, and mortality. Despite guideline recommendations for risk stratification and allergy delabeling, implementation remains limited. PEN-FAST is a validated clinical tool used to facilitate delabeling without resource-intensive skin testing. This study aimed to determine the prevalence of low-risk penicillin allergy among adult patients using the PEN-FAST tool within a pharmacist-led medication reconciliation process. METHODS: A multicenter, retrospective prevalence study was conducted at 2 community hospitals. Patients admitted or seen in the emergency department from September 16 through December 16, 2024, with a documented penicillin allergy who underwent a pharmacist-performed PEN-FAST assessment were included. The primary outcome was the proportion of patients classified as having low-risk penicillin allergy (PEN-FAST score of <3). Secondary outcomes included allergy delabeling rates and the frequency of direct oral penicillin challenges. Descriptive analysis was used to evaluate the results. RESULTS: Of 95 patients assessed, 74% (n = 70) were classified as low risk. Among these low-risk patients, 10% (n = 7) had their allergy label removed and 3% (n = 2) underwent a direct oral penicillin challenge, with both tolerating penicillin without adverse reactions. CONCLUSION: These findings suggest that pharmacist-led PEN-FAST implementation is a feasible strategy to identify low-risk penicillin allergies, but allergy delabeling and oral challenge rates remain low. Further efforts are needed to integrate PEN-FAST into clinical workflows and enhance antimicrobial stewardship.
引用
- Linville S, Metzger A, Etemady-Deylamy A, et al. Think PEN-FAST: Evaluation of implementing PEN-FAST into pharmacist-led medication reconciliation. Am J Health Syst Pharm. 2026. PMID: 42033754. doi:10.1093/ajhp/zxag129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。